Mental health clinicians often ask for a single, black-and-white answer to the question: Which lab tests should I order before starting this particular medication? Inevitably, the answer is that it depends. Here are some guidelines that are useful.
Read More
Dr. Schildkrout discusses strategies for differentiating medical and psychiatric disorders. The interview covers how mental health professionals can catch red flags for medical conditions such as dimentia and seizures.
Read More
On September 17, the FDA approved cariprazine (Vraylar) for the treatment of schizophrenia and bipolar disorder. There’s already some buzz about whether this medication has advantages over other atypicals for treating negative symptoms of schizophrenia. Read More
Catching patients early in the course of their psychotic disorders may improve outcomes. A new NIMH-funded study compared a very comprehensive treatment program with treatment as usual, and the results were promising.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
